What Patients Should Know About Tysabri and PML Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Tysabri Safety

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML)—a rare but serious brain infection. Decades of pharmacovigilance have established a clear understanding of this risk, including key factors like JC virus antibody status and duration of therapy. This page provides an objective overview of PML symptoms, risk stratification, and monitoring strategies to help you have an informed conversation with your healthcare provider.

Clinical and Pharmacological Context of Tysabri and PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease under specific limitations. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative integrates clinical, pharmacological, and legal considerations based on available evidence. PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring in immunocompromised individuals. It usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because prompt intervention may improve outcomes, though the disease remains devastating.

Mechanisms and Risk Factors for Tysabri-Associated PML

Tysabri is a monoclonal antibody that inhibits alpha-4 integrin, reducing immune cell trafficking into the central nervous system. While this mechanism effectively controls MS inflammation, it also impairs immune surveillance, creating an environment permissive for JC virus reactivation. In clinical trials, PML occurred in three patients receiving Tysabri. Two cases were observed among 1869 MS patients treated for a median of 120 weeks, both of whom had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore that PML risk is not limited to long-term therapy but can emerge relatively early. The primary mechanism involves Tysabri's blockade of lymphocyte adhesion molecules, preventing immune cells from crossing the blood-brain barrier. This reduces central nervous system immune surveillance, allowing latent JC virus to reactivate and infect oligodendrocytes, leading to demyelination. Three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.

Adequacy of Warnings and Legal Considerations

The prescribing information for Tysabri includes a boxed warning stating that the drug increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also notes that risk factors include anti-JCV antibodies, treatment duration, and prior immunosuppressant use. Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, designed to ensure informed risk-benefit discussions and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and providers fully understand the magnitude of risk, particularly given the potential for severe outcomes. Patients who develop PML after Tysabri treatment may consider legal action if they believe warnings were inadequate or if their specific risk factors were not properly assessed. Key considerations include whether the prescribing physician discussed the boxed warning and risk factors, whether anti-JCV antibody testing was performed, and whether the patient's prior immunosuppressant use was considered. The TOUCH program requires documentation of informed consent, but deviations from protocol could be relevant. Affected individuals should consult with an attorney experienced in pharmaceutical litigation to evaluate their case based on medical records and prescribing practices.

Timeline Between Exposure and Documented Harm

The onset of PML can vary. In clinical trials, one case occurred after eight doses in a Crohn's disease patient, while two MS cases emerged after a median of 120 weeks of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability means that harm can occur within months or after several years. Early symptoms may be subtle, and diagnosis can be delayed, worsening prognosis. Patients and providers must remain vigilant throughout treatment, as risk increases with longer exposure.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of reducing immune surveillance in the central nervous system (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal criteria are considered in Tysabri PML lawsuits?

Lawsuits often consider whether the prescribing physician adequately warned about PML risks, performed anti-JCV antibody testing, and considered prior immunosuppressant use. Deviations from the TOUCH program protocol may also be relevant. Affected individuals should consult an attorney experienced in pharmaceutical litigation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.